The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis

The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis

Metabolic dysfunction-associated steatotic liver disease (MASLD)—formerly known as non-alcoholic fatty liver disease (NAFLD)—is the most common chronic liver disease worldwide. Since there is currently no approved pharmacotherapy for MASLD, there is an urgent unmet need for efficacious therapeutics...

Full description

Bibliographic Details
Main Authors: Yvonne Burmeister, Kathrin Weyer, Achim Dörre, Bernd Seilheimer
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Biomedicines
Subjects:
non-alcoholic fatty liver disease (NAFLD)
non-alcoholic steatohepatitis (NASH)
metabolic dysfunction-associated steatotic liver disease (MASLD)
metabolic dysfunction-associated steatohepatitis (MASH)
liver
fibrosis
Online Access:https://www.mdpi.com/2227-9059/11/12/3216

Similar Items

Similar Items